Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-10

Study Completion Date

2024-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study purpose is to conduct a confirmatory double-blind randomized controlled trial in an inpatient setting of the effects of a tightly controlled gluten-free diet (GFD) to improve negative symptoms in people with schizophrenia or schizoaffective disorder who have antibodies to gliadin (AGA IgG). As part of the project investigators will also confirm outcomes such as cognitive symptoms, changes in peripheral and central inflammation as well as gut/blood brain barrier permeability.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive

NCT01927276

Schizophrenia

COMPLETED NA

Gluten Free Diet in People With Schizophrenia: A Pilot Study

NCT01558557

Gluten Sensitivity Celiac Disease

COMPLETED NA

Prebiotic Treatment in People With Schizophrenia

NCT05527210

Schizophrenia Schizoaffective Disorder

RECRUITING NA

Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia

NCT00575848

Schizophrenia Schizoaffective Disorder

TERMINATED PHASE1

Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)

NCT00725075

Schizophrenia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized double blind clinical trial being funded by NIMH. Investigators will need to enroll 40 cases with AGA IgG positivity in order to present a powered and convincing result about the efficacy of gluten withdrawal in the subpopulation of persons with schizophrenia with elevated AGA IgG levels. Investigators will recruit a minimum 50 to ensure they are well powered without question, and to account for dropouts. Investigators will use a battery of measures of peripheral and central inflammation as well as gut permeability at baseline and endpoint to confirm the relationship of these outcomes to changes in AGA IgG and symptom changes in the clinical trial. Investigators will test negative symptoms as a primary outcome but will test changes in other symptom domains such as positive symptoms. After the completion of the 5 week confirmatory study, investigators will discharge participants and follow them for 8 weeks in their own environment to test the maintenance of the effect following the stringent GFD, and provide education on gluten free shopping, cooking and eating.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Gluten Sensitivity Schizo Affective Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized double blind trial

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gluten

30 grams of gluten flour daily in protein shake

Group Type ACTIVE_COMPARATOR

Gluten Flour in Protein Shake

Intervention Type OTHER

15 Grams Gluten Flour BID

Placebo

30 grams of rice flour daily in protein shake

Group Type PLACEBO_COMPARATOR

Rice Flour in Protein Shake

Intervention Type OTHER

15 Grams Rice Flour BID

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gluten Flour in Protein Shake

15 Grams Gluten Flour BID

Intervention Type OTHER

Rice Flour in Protein Shake

15 Grams Rice Flour BID

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. DSM-IV/DSM 5 diagnosis of schizophrenia or schizoaffective disorder
2. Positive for antibodies to gliadin (IgG \> 20 U)
3. SANS total score ≥ 20 and the affective flattening or alogia global item ≥ 3
4. Age 18- 64 years
5. Same antipsychotic for at least 4 weeks
6. Ability to consent determined by a score of 10 or greater on the Evaluation to Sign Consent.

Exclusion Criteria

1. Persons already on gluten free diets
2. Positivity to tissue transglutaminase (tTg) antibodies or known history of Celiac Disease
3. Pregnant or lactating females
4. Medical condition whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol
5. Meets DSM-5 criteria for alcohol or substance use disorder (other than nicotine) within the last month
6. Gluten ataxia, as measured by the Brief Ataxia Rating Scale

Additional exclusion for those participating in optional imaging component:
7. Non-removable ferromagnetic metal on or within the body
8. Current claustrophobia
9. Inability to lie supine for 1.5 hours

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No